GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mesoblast Ltd (ASX:MSB) » Definitions » Cyclically Adjusted PS Ratio

Mesoblast (ASX:MSB) Cyclically Adjusted PS Ratio : (As of Jun. 11, 2024)


View and export this data going back to 2004. Start your Free Trial

What is Mesoblast Cyclically Adjusted PS Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Mesoblast Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Mesoblast's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mesoblast Cyclically Adjusted PS Ratio Chart

Mesoblast Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 29.97 9.53 18.32

Mesoblast Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 15.06 18.32 - - -

Competitive Comparison of Mesoblast's Cyclically Adjusted PS Ratio

For the Biotechnology subindustry, Mesoblast's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Mesoblast's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Mesoblast's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Mesoblast's Cyclically Adjusted PS Ratio falls into.



Mesoblast Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Mesoblast's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, Mesoblast's adjusted Revenue per Share data for the three months ended in Dec. 2023 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=0/126.3989*126.3989
=0.000

Current CPI (Dec. 2023) = 126.3989.

Mesoblast Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201306 0.000 95.473 0.000
201312 0.000 97.330 0.000
201406 0.000 98.352 0.000
201412 0.016 99.002 0.020
201503 0.016 99.187 0.020
201506 0.015 99.838 0.019
201509 0.030 100.302 0.038
201512 0.015 100.673 0.019
201603 0.014 100.488 0.018
201606 0.087 100.859 0.109
201609 0.001 101.602 0.001
201612 0.001 102.159 0.001
201703 0.003 102.624 0.004
201706 0.001 102.809 0.001
201709 0.003 103.460 0.004
201712 0.035 104.110 0.042
201803 0.003 104.574 0.004
201806 0.004 104.945 0.005
201809 0.032 105.410 0.038
201812 0.005 105.967 0.006
201903 0.003 105.967 0.004
201906 0.007 106.617 0.008
201909 0.048 107.174 0.057
201912 0.005 107.917 0.006
202003 0.034 108.289 0.040
202006 0.002 106.246 0.002
202009 0.003 107.917 0.004
202012 0.005 108.846 0.006
202103 0.004 109.496 0.005
202106 0.004 110.332 0.005
202109 0.007 111.168 0.008
202112 0.005 112.654 0.006
202203 0.004 115.069 0.004
202206 0.005 117.112 0.005
202209 0.003 119.248 0.003
202212 0.004 121.477 0.004
202303 0.004 123.148 0.004
202306 0.004 124.170 0.004
202309 0.000 125.656 0.000
202312 0.000 126.399 0.000

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Mesoblast  (ASX:MSB) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Mesoblast Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Mesoblast's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Mesoblast (ASX:MSB) Business Description

Industry
Traded in Other Exchanges
Address
Level 38, 55 Collins Street, Melbourne, VIC, AUS, 3000
Mesoblast Ltd is a clinical-stage biotechnology company. It develops and commercializes innovative allogeneic cellular medicines to treat complex diseases resistant to the conventional standard of care. Its portfolio of Phase 3 product candidates comprises remestemcel-L for the treatment of steroid-refractory acute graft versus host disease (SR-aGVHD), and for moderate to severe acute respiratory distress syndrome (ARDS) and others.

Mesoblast (ASX:MSB) Headlines